ONEOK Returns to Buy Range on Valuation and Guidance Uplift
Read source articleWhat happened
ONEOK's share price has pulled back into a range that Seeking Alpha now labels a Buy, after previously being rated Hold, driven by valuation and growth prospects. The stock trades at 7.7x forward operating cash flow, a 21% discount to the author's $111 fair value estimate, implying potential for 12%+ annual returns through 2031. Management has raised the 2026 adjusted EBITDA midpoint to $8.55 billion, supported by Brazos assets and new project contributions that underpin volume growth. Our internal DeepValue master report maintains a POTENTIAL BUY rating with a conviction of 3.5, an attractive entry at $72, and a base-case implied value of $85, reflecting a more conservative stance than the article. Key risks include elevated leverage at 4.8x net debt/EBITDA and a payout ratio above 100% of free cash flow, which could pressure the dividend if execution stalls.
Implication
Investors may consider accumulating OKE near current levels, but should recognize that the $111 fair value target is more bullish than our base case of $85 and depends on sustained volume growth and successful project execution. The raised 2026 EBITDA guidance is a positive signal, but it must be reconciled with the company's high net debt/EBITDA of 4.8x and the need to fund a $2.8–3.2 billion annual capex program while maintaining the dividend. A disciplined approach would involve monitoring quarterly leverage metrics and free cash flow coverage, as failure to deleverage toward 3.5x could invalidate the upside thesis and push the stock toward the bear-case $65. The fee-based revenue model and contracted capacity provide some downside protection, but the stock is not a low-risk bond proxy given its payout ratio and reliance on continued basin growth. Overall, OKE offers an attractive risk-reward for patient investors who can tolerate volatility and verify that management's guidance translates into actual EBITDA and debt reduction over the next 6–12 months.
Thesis delta
The article's upgrade to Buy aligns with our existing POTENTIAL BUY rating, but its $111 fair value is significantly above our base-case implied value of $85, suggesting the author may be overestimating long-term growth and execution certainty. The raised 2026 EBITDA midpoint to $8.55 billion slightly improves the near-term outlook but does not materially change our assessment of balanced risk, as leverage and free cash flow coverage remain key constraints. No change to our rating or target, but the article reinforces the valuation opportunity while reminding us to remain critical of overly optimistic return projections.
Confidence
Medium-High